Voltar
Carta Acesso aberto Revisado por pares
BIBTEX RIS

Addition of Corticosteroids to Immunoglobulins Is Associated With Recovery of Cardiac Function in Multi-Inflammatory Syndrome in Children

2020; Lippincott Williams & Wilkins; Volume: 142; Issue: 23 Linguagem: Inglês

10.1161/circulationaha.120.050147

ISSN

1524-4539

Autores

Zahra Belhadjer, Johanne Auriau, Mathilde Méot, Mehdi Oualha, Sylvain Renolleau, Lucile Houyel, Damien Bonnet,

Tópico(s)

Cardiovascular Issues in Pregnancy

Resumo

HomeCirculationVol. 142, No. 23Addition of Corticosteroids to Immunoglobulins Is Associated With Recovery of Cardiac Function in Multi-Inflammatory Syndrome in Children Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBAddition of Corticosteroids to Immunoglobulins Is Associated With Recovery of Cardiac Function in Multi-Inflammatory Syndrome in Children Zahra Belhadjer, MD, Johanne Auriau, MD, Mathilde Méot, MD, Mehdi Oualha, MD, PhD, Sylvain Renolleau, MD, PhD, Lucile Houyel, MD and Damien Bonnet, MD, PhD Zahra BelhadjerZahra Belhadjer M3C-Necker Enfants malades, AP-HP, Paris, France (Z.B., J.A., M.M., L.H., D.B.). Université de Paris, France (Z.B., J.A., M.O., S.R., L.H., D.B.). , Johanne AuriauJohanne Auriau M3C-Necker Enfants malades, AP-HP, Paris, France (Z.B., J.A., M.M., L.H., D.B.). Université de Paris, France (Z.B., J.A., M.O., S.R., L.H., D.B.). , Mathilde MéotMathilde Méot https://orcid.org/0000-0001-9306-5580 M3C-Necker Enfants malades, AP-HP, Paris, France (Z.B., J.A., M.M., L.H., D.B.). , Mehdi OualhaMehdi Oualha Université de Paris, France (Z.B., J.A., M.O., S.R., L.H., D.B.). Pediatric Intensive Care Unit, Necker Enfants Malades, AP-HP, Paris, France (M.O., S.R.). , Sylvain RenolleauSylvain Renolleau https://orcid.org/0000-0002-0638-5613 Université de Paris, France (Z.B., J.A., M.O., S.R., L.H., D.B.). Pediatric Intensive Care Unit, Necker Enfants Malades, AP-HP, Paris, France (M.O., S.R.). , Lucile HouyelLucile Houyel M3C-Necker Enfants malades, AP-HP, Paris, France (Z.B., J.A., M.M., L.H., D.B.). Université de Paris, France (Z.B., J.A., M.O., S.R., L.H., D.B.). and Damien BonnetDamien Bonnet Damien Bonnet, MD, PhD, Unité Médico-Chirurgicale de Cardiologie Congénitale et Pédiatrique, Centre de Référence des Malformations Cardiaques Congénitales Complexes M3C, Hôpital Necker-Enfants Malades, APHP, 149 Rue de Sèvres, 75015 Paris, France. Email E-mail Address: [email protected] Université de Paris, France (Z.B., J.A., M.O., S.R., L.H., D.B.). UMR-1163 INSERM, Institut IMAGINE, IcarP Cardiology, Paris, France (D.B.). Originally published28 Oct 2020https://doi.org/10.1161/CIRCULATIONAHA.120.050147Circulation. 2020;142:2282–2284Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: October 28, 2020: Ahead of Print An entity related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection associated with a multisystem inflammatory state in children (MIS-C) and acute heart failure has been described.1 Early treatment of MIS-C has mimicked that of Kawasaki disease with the use of intravenous immunoglobulin (IVIG) and other anti-inflammatory agents.1–3 This strategy seems to be effective because the outcomes are usually favorable with a very limited number of fatalities.1,3 Yet, there is no consensus or evidence for the optimal treatment strategy in MIS-C, and the effect of treatment strategies on the recovery of cardiac function has not been yet described.We report the evolution of cardiac function in children admitted at our institution for MIS-C, defined by persistent fever (>38.5 °C) for >3 days, multiorgan involvement, evidence for coagulopathy (D-dimers>1000 ng/mL), inflammation (C-reactive protein>80 mg/L), and positive antibody assays for SARS-CoV-2 infection. Three clinical criteria among the following had to be observed to define multiorgan involvement in this series: cervical lymphadenopathy, bulbar conjunctivitis, skin rash, erythema of oral and pharyngeal mucosa, gastrointestinal symptoms, asthenia, respiratory signs, heart failure, or cardiogenic shock.Median age was 8.6 years (interquartile range [IQR], 6.7–11.2). The median delay between symptom onset and hospital admission was 4 days and was stable over the study period. All patients had positive assays for SARS-CoV-2 antibodies. Echocardiographic monitoring was regularly performed from admission to discharge. Eighteen patients admitted before May 1, 2020, received IVIG (2g/kg once) as first-line treatment, and the 22 patients admitted after this date received a combination of IVIG and intravenous methylprednisolone (0.8 mg·kg–1·d–1 for 5 days). These 2 populations had similar clinical, cardiac, and biological characteristics at baseline. The study was approved by the local ethics committee that waived the need for parental informed consent (authorization number: MR004: 2020–0505172058).The cumulative incidence to recovery defined as left ventricle ejection fraction [LVEF] >55% for systolic function and isovolumic relaxation time (IVRT) >90 ms for diastolic function was calculated using the Kaplan-Meier approach (IBM SPSS version 23 statistical software).At the time of admission, LVEF was 55%) was 4 days (IQR, 2–6), and median time to recovery of IVRT (>90 ms) was 7 days (IQR, 4–17). The main finding was the reduction of time to recovery of LVEF and IVRT, and pediatric intensive care unit stay in the group receiving a combination of IVIG and steroids in comparison with the group receiving only IVIG, respectively, 2.9 versus 5.4 days, 6.4 versus 20.6 days, and 3.4 versus 5.3 days (P<0.05) (Figure). Left main coronary artery zscore was 0 (IQR, –0.7 to 0.6) at baseline and –0.5 (IQR, –1.3 to 0) at discharge without significant differences between the groups.Download figureDownload PowerPointFigure. Kaplan-Meier recovery curves, along with the 95% confidence interval for patients who received intravenous immunoglobulin and steroid treatment (dashed line) versus those who were treated with intravenous immunoglobulin only (full line). A, LVEF recovery. (Only 29 of 40 patients who had LVEF<55% at admission were included in this analysis.) B, IVRT recovery. (IVRT was measured at admission in 30 of 40 patients who all had sequential evaluations.) IVRT indicates isovolumic relaxation time; and LVEF, left ventricular ejection fraction.Acute left ventricular systolic and diastolic dysfunction are prominent findings in MIS-C. All recent reports show that B-type natriuretic peptide or N-terminal pro B-type natriuretic peptide levels are very high, whereas troponin elevation is usually mild to moderate.1,3 Together with the rapid recovery of cardiac function, these findings are in favor of myocardial stunning rather than myocarditis in MIS-C. A recent cardiac magnetic resonance study in patients with MIS-C reported evidence of myocardial edema with no late gadolinium enhancement that would be suggestive of necrosis.4Patients with MIS-C appear to be responsive to IVIG.1,3 Still, there is no direct evidence that IVIG improves outcomes in MIS-C2 or that an adjunct of other anti-inflammatory agents is effective. To resolve the severe inflammatory state associated with MIS-C, some children have been successfully treated with steroids, anakinra, an interleukin-1 receptor antagonist, or with infliximab.1,3 During the second period of our series, we added steroids to target systemic inflammation and reduce cytokine storm. Recent data suggest some benefit of corticosteroid therapy in the treatment of inflammatory lung complications of coronavirus disease 2019 (COVID-19), and corticosteroids could play a similar role in other later inflammatory complications of SARS-CoV-2 infection such as MIS-C.5The major limitation of our study is the absence of randomization, but it was not possible to set up this type of trial in the context of a severe emerging syndrome. Increasing awareness on MIS-C and more standardized management could have influenced outcomes, but the day of admission and cardiac parameters were similar in the 2 study groups.This observational study suggests that adding corticosteroids to immunoglobulins is associated with a shorter time to recovery of cardiac function in patients with MIS-C. Further evaluation in randomized controlled trials is needed to confirm these findings and to define the optimal treatment strategy in MIS-C.DisclosuresNone.Footnotes*Drs Houyel and Bonnet are co–senior authors.https://www.ahajournals.org/journal/circData are available on request.Damien Bonnet, MD, PhD, Unité Médico-Chirurgicale de Cardiologie Congénitale et Pédiatrique, Centre de Référence des Malformations Cardiaques Congénitales Complexes M3C, Hôpital Necker-Enfants Malades, APHP, 149 Rue de Sèvres, 75015 Paris, France. Email damien.[email protected]comReferences1. Belhadjer Z, Méot M, Bajolle F, Khraiche D, Legendre A, Abakka S, Auriau J, Grimaud M, Oualha M, Beghetti M, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic.Circulation. 2020; 142:429–436. doi: 10.1161/CIRCULATIONAHA.120.048360LinkGoogle Scholar2. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association [published correction appears in Circulation. 2019;140:e181–e184].Circulation. 2017; 135:e927–e999AbstractGoogle Scholar3. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, Ramnarayan P, Fraisse A, Miller O, Davies P, et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2.JAMA. 2020; 324:259–269. doi: 10.1001/jama.2020.10369CrossrefMedlineGoogle Scholar4. Blondiaux E, Parisot P, Redheuil A, Tzaroukian L, Levy Y, Sileo C, Schnuriger A, Lorrot M, Guedj R, Ducou le Pointe H. Cardiac MRI of children with multisystem inflammatory syndrome (MIS-C) associated with COVID-19: case series.Radiology. 2020202288. doi: 10.1148/radiol.2020202288Google Scholar5. RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, et al. Dexamethasone in hospitalized patients with Covid-19–preliminary report [published online July 17, 2020].N Engl J Med. doi: 10.1056/NEJMoa2021436Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Villacis-Nunez D, Jones K, Jabbar A, Fan L, Moore W, Peter A, Henderson M, Xiang Y, Kelleman M, Sherry W, Chandrakasan S, Oster M, Jaggi P and Prahalad S (2022) Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children, JAMA Pediatrics, 10.1001/jamapediatrics.2022.0292, 176:6, (576), Online publication date: 1-Jun-2022. Pal P, Bathia J, De H, Biswas D, Bhelo M and Mondal A (2022) A retrospective analysis of the need for methylprednisolone in addition to IVIG for treating multisystem inflammatory syndrome in children, Rheumatology, 10.1093/rheumatology/keac086, 61:6, (e141-e142), Online publication date: 30-May-2022. Patel J (2022) Multisystem Inflammatory Syndrome in Children (MIS-C), Current Allergy and Asthma Reports, 10.1007/s11882-022-01031-4, 22:5, (53-60), Online publication date: 1-May-2022. Wang Z, Zhao S, Tang Y, Wang Z, Shi Q, Dang X, Gan L, Peng S, Li W, Zhou Q, Li Q, Mafiana J, Cortés R, Luo Z, Liu E and Chen Y (2022) Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review, European Journal of Pediatrics, 10.1007/s00431-022-04388-w, 181:5, (2135-2146), Online publication date: 1-May-2022. Maggi E, Azzarone B, Canonica G and Moretta L (2021) What we know and still ignore on COVID‐19 immune pathogenesis and a proposal based on the experience of allergic disorders, Allergy, 10.1111/all.15112, 77:4, (1114-1128), Online publication date: 1-Apr-2022. Brück N, Schütz C and Kallinich T (2022) Das Pädiatrische Inflammatorische Multisystem Syndrom (PIMS) in der COVID-19 Pandemie, Aktuelle Rheumatologie, 10.1055/a-1715-5027, 47:02, (117-127), Online publication date: 1-Apr-2022. Henderson L, Canna S, Friedman K, Gorelik M, Lapidus S, Bassiri H, Behrens E, Kernan K, Schulert G, Seo P, Son M, Tremoulet A, VanderPluym C, Yeung R, Mudano A, Turner A, Karp D and Mehta J (2022) American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 3, Arthritis & Rheumatology, 10.1002/art.42062, 74:4, Online publication date: 1-Apr-2022. Rauniyar R, Mishra A, Kharel S, Giri S, Rauniyar R, Yadav S, Chaudhary G and Zhang K (2022) IVIG plus Glucocorticoids versus IVIG Alone in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Systematic Review and Meta-Analysis, Canadian Journal of Infectious Diseases and Medical Microbiology, 10.1155/2022/9458653, 2022, (1-7), Online publication date: 29-Mar-2022. Huang J, Gaines S, Amezcua M, Lubell T, Dayan P, Dale M, Boneparth A, Hicar M, Winchester R and Gorelik M (2022) Upregulation of type 1 conventional dendritic cells implicates antigen cross-presentation in multisystem inflammatory syndrome, Journal of Allergy and Clinical Immunology, 10.1016/j.jaci.2021.10.015, 149:3, (912-922), Online publication date: 1-Mar-2022. Mahmoud S, El-Kalliny M, Kotby A, El-Ganzoury M, Fouda E and Ibrahim H (2022) Treatment of MIS-C in Children and Adolescents, Current Pediatrics Reports, 10.1007/s40124-021-00259-4, 10:1, (1-10), Online publication date: 1-Mar-2022. Truong D, Dionne A, Muniz J, McHugh K, Portman M, Lambert L, Thacker D, Elias M, Li J, Toro-Salazar O, Anderson B, Atz A, Bohun C, Campbell M, Chrisant M, D'Addese L, Dummer K, Forsha D, Frank L, Frosch O, Gelehrter S, Giglia T, Hebson C, Jain S, Johnston P, Krishnan A, Lombardi K, McCrindle B, Mitchell E, Miyata K, Mizzi T, Parker R, Patel J, Ronai C, Sabati A, Schauer J, Sexson Tejtel S, Shea J, Shekerdemian L, Srivastava S, Votava-Smith J, White S and Newburger J (2021) Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination, Circulation, 145:5, (345-356), Online publication date: 1-Feb-2022. Abrams J, Belay E, Godfred-Cato S, Campbell A, Zambrano L, Kunkel A, Miller A, Wu M, Meng L, Shah A and Oster M (2022) Trends in Treatments for Multisystem Inflammatory Syndrome in Children (MIS-C), United States, February 2020 – July 2021, Clinical Infectious Diseases, 10.1093/cid/ciac072 Mahdavi M, Hejri G, Pouraliakbar H, Shahzadi H, Hesami M and Houshmand G (2021) Cytokine storm after heart transplantation in COVID‐19‐related haemophagocytic lymphohistiocytosis (HLH), ESC Heart Failure, 10.1002/ehf2.13728, 9:1, (219-223), Online publication date: 1-Feb-2022. Mastrolia M, Marrani E, Maccora I, Pagnini I and Simonini G (2021) The Role of Anti-IL-1 Treatment in MIS-C Patients, Expert Opinion on Biological Therapy, 10.1080/14712598.2022.2006631, 22:1, (1-5), Online publication date: 2-Jan-2022. Dionne A, Son M and Randolph A (2021) An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2, Pediatric Infectious Disease Journal, 10.1097/INF.0000000000003393, 41:1, (e6-e9), Online publication date: 1-Jan-2022. Ko R, Massa C, Saraiya N and Cheung E (2021) Multisystem Inflammatory Syndrome in Children (MIS-C): Experiences With a New Disease Process, Journal of Neurosurgical Anesthesiology, 10.1097/ANA.0000000000000811, 34:1, (127-131), Online publication date: 1-Jan-2022. Brisca G, Consolaro A, Caorsi R, Pirlo D, Tuo G, Campanello C, Castagnola E, Moscatelli A, Gattorno M and Ravelli A (2021) Timely Recognition and Early Multi-Step Antinflammatory Therapy May Prevent ICU Admission of Patients With MIS-C: Proposal for a Severity Score, Frontiers in Pediatrics, 10.3389/fped.2021.783745, 9 Mastrolia M, Marrani E, Calabri G, L'Erario M, Maccora I, Favilli S, Duchini P, Pagnini I and Simonini G (2021) Fast recovery of cardiac function in PIMS-TS patients early using intravenous anti-IL-1 treatment, Critical Care, 10.1186/s13054-021-03548-y, 25:1, Online publication date: 1-Dec-2021. Vella L and Rowley A (2021) Current Insights Into the Pathophysiology of Multisystem Inflammatory Syndrome in Children, Current Pediatrics Reports, 10.1007/s40124-021-00257-6, 9:4, (83-92), Online publication date: 1-Dec-2021. Wang L, Li G, Yuan C, Yang Y, Ling G, Zheng J, Zhou Y, Zhang T, Lin W and Lin Z (2021) Progress in the Diagnosis and Treatment of COVID-19 in Children: A Review, International Journal of General Medicine, 10.2147/IJGM.S335888, Volume 14, (8097-8108) Vukomanovic V, Krasic S, Prijic S, Ninic S, Popovic S, Petrovic G, Ristic S, Simic R, Cerovic I and Nesic D (2021) Recent Experience: Corticosteroids as a First-line Therapy in Children With Multisystem Inflammatory Syndrome and COVID-19-related Myocardial Damage, Pediatric Infectious Disease Journal, 10.1097/INF.0000000000003260, 40:11, (e390-e394), Online publication date: 1-Nov-2021. Case S and Son M (2021) COVID-19 in Pediatrics, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2021.07.006, 47:4, (797-811), Online publication date: 1-Nov-2021. Do M, Stewart C and Harp J (2021) Cutaneous Manifestations of COVID-19 in the Inpatient Setting, Dermatologic Clinics, 10.1016/j.det.2021.05.011, 39:4, (521-532), Online publication date: 1-Oct-2021. Roberts J and Henderson L (2021) Clinical features of multisystem inflammatory syndrome in children, Current Opinion in Rheumatology, 10.1097/BOR.0000000000000818, 33:5, (378-386), Online publication date: 1-Sep-2021. Crosby L, Balasubramanian S and Ramanan A (2021) Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs, The Lancet Rheumatology, 10.1016/S2665-9913(21)00223-X, 3:9, (e615-e616), Online publication date: 1-Sep-2021. Farooqi K, Chan A, Weller R, Mi J, Jiang P, Abrahams E, Ferris A, Krishnan U, Pasumarti N, Suh S, Shah A, DiLorenzo M, Zachariah P, Milner J, Rosenzweig E, Gorelik M and Anderson B (2021) Longitudinal Outcomes for Multisystem Inflammatory Syndrome in Children, Pediatrics, 10.1542/peds.2021-051155, 148:2, Online publication date: 1-Aug-2021. Belay E, Abrams J, Oster M, Giovanni J, Pierce T, Meng L, Prezzato E, Balachandran N, Openshaw J, Rosen H, Kim M, Richardson G, Hand J, Tobin-D'Angelo M, Wilson S, Hartley A, Jones C, Kolsin J, Mohamed H, Colles Z, Hammett T, Patel P, Stierman B, Campbell A and Godfred-Cato S (2021) Trends in Geographic and Temporal Distribution of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic, JAMA Pediatrics, 10.1001/jamapediatrics.2021.0630, 175:8, (837), Online publication date: 1-Aug-2021. Takia L, Angurana S, Nallasamy K, Bansal A and Muralidharan J (2021) Updated Management Protocol for Multisystem Inflammatory Syndrome in Children (MIS-C), Journal of Tropical Pediatrics, 10.1093/tropej/fmab071, 67:3, Online publication date: 2-Jul-2021. Suresh Kumar A, Awasthi P, Thakur A, Randhawa M, Nallasamy K, Kumar M, Naganur S, Kumar M, Goyal K, Ghosh A, Bansal A and Jayashree M (2021) Intensive Care Needs and Short-Term Outcome of Multisystem Inflammatory Syndrome in Children (MIS-C): Experience from North India, Journal of Tropical Pediatrics, 10.1093/tropej/fmab055, 67:3, Online publication date: 2-Jul-2021. McArdle A, Vito O, Patel H, Seaby E, Shah P, Wilson C, Broderick C, Nijman R, Tremoulet A, Munblit D, Ulloa-Gutierrez R, Carter M, De T, Hoggart C, Whittaker E, Herberg J, Kaforou M, Cunnington A and Levin M (2021) Treatment of Multisystem Inflammatory Syndrome in Children, New England Journal of Medicine, 10.1056/NEJMoa2102968, 385:1, (11-22), Online publication date: 1-Jul-2021. Son M, Murray N, Friedman K, Young C, Newhams M, Feldstein L, Loftis L, Tarquinio K, Singh A, Heidemann S, Soma V, Riggs B, Fitzgerald J, Kong M, Doymaz S, Giuliano J, Keenaghan M, Hume J, Hobbs C, Schuster J, Clouser K, Hall M, Smith L, Horwitz S, Schwartz S, Irby K, Bradford T, Maddux A, Babbitt C, Rowan C, McLaughlin G, Yager P, Maamari M, Mack E, Carroll C, Montgomery V, Halasa N, Cvijanovich N, Coates B, Rose C, Newburger J, Patel M and Randolph A (2021) Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes, New England Journal of Medicine, 10.1056/NEJMoa2102605, 385:1, (23-34), Online publication date: 1-Jul-2021. Sancho-Shimizu V, Brodin P, Cobat A, Biggs C, Toubiana J, Lucas C, Henrickson S, Belot A, Haddad E, Beland K, Pujol A, Schlüter A, Planas-Serra L, Aguilera-Albesa S, Valencia-Ramos J, Rodríguez-Palmero A, Gut M, Rivière J, Colobran R, Soler-Palacin P, Rodriguez-Gallego C, Perez De Diego R, Flores C, Alsina L, Blazquez-Gamero D, Jordan I, Keles S, Emiroglu M, Akcan O, Alkan G, Aytekin S, Gul Y, Tüter Öz Ş, Bozdemir S, Bayhan G, Yüksek S, Parlakay A, Gülhan B, Yahşi A, Kilic A, Karbuz A, Erdeniz E, Özkan E, Orbak Z, Aydemir Ş, Celik J, Kandemir B, Aytekin G, Kapakli H, Yarar V, Yosunkaya A, Vatansev H, Aytekin C, Torun S, Nepesov S, Coskuner T, Sözeri B, Demirkol Y, Kasapcopur O, Yıldız M, Sevketoglu E, Hatipoğlu N, Özçelik T, Yesilbas O, Gayretli Aydin Z, Sediva A, Klocperk A, Bloomfield M, Meyts I, Delafontaine S, Haerynck F, Hoste L, Shahrooei M, Marque L, Neves J, Novelli G, Novelli A, Aiuti A, Casari G, Bousfiha A, Almuhsen S, Sobh A, Gagro A, Bajolle F, Bonnet D, Lebon P, Lei W, Lee D, Seeleuthner Y, Zhang P, Maglorius M, Philippot Q, Pelham S, Bastard P, Zhang Q, Jouanguy E, Puel A, Herberg J, Kuijpers T, Bellos E, Kaforou M, Menikou S, Pan-Hammarström Q, Hammarström L, Abolhassani H, Bryceson Y, Condino-Neto A, Prando C, Bando S, Cavalcanti A, Fellay J, Blanchard-Rohner G, Mansouri D, Mahmoudi S, Boyarchuk O, Volokha A, Bondarenko A, Stepanovskiy Y, Mogensen T, van de Beek D, Andreakos E, Papadaki M, Abou Tayoun A, Halwani R, Al-Mulla F, Franco J, Lau Y, Kwan M, Imai K, Okada S, Bolze A, Butte M, Hsieh E, Drolet B, Arkin L, Itan Y, Maniatis T, Arditi M, Cooper M, Schmitt E, Chakravorty S, Anderson M, Su H, Notarangelo L, Tangye S, Milner J, Levin M, Abel L, Bogunovic D, Casanova J and Zhang S (2021) SARS-CoV-2–related MIS-C: A key to the viral and genetic causes of Kawasaki disease?, Journal of Experimental Medicine, 10.1084/jem.20210446, 218:6, Online publication date: 7-Jun-2021. Schlapbach L, Andre M, Grazioli S, Schöbi N, Ritz N, Aebi C, Agyeman P, Albisetti M, Bailey D, Berger C, Blanchard-Rohner G, Bressieux-Degueldre S, Hofer M, L'Huillier A, Marston M, Meyer Sauteur P, Pachlopnik Schmid J, Perez M, Rogdo B, Trück J, Woerner A, Wütz D, Zimmermann P, Levin M, Whittaker E and Rimensberger P (2021) Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland, Frontiers in Pediatrics, 10.3389/fped.2021.667507, 9 Coopersmith C, Antonelli M, Bauer S, Deutschman C, Evans L, Ferrer R, Hellman J, Jog S, Kesecioglu J, Kissoon N, Martin-Loeches I, Nunnally M, Prescott H, Rhodes A, Talmor D, Tissieres P and De Backer D (2021) The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness, Critical Care Medicine, 10.1097/CCM.0000000000004895, 49:4, (598-622), Online publication date: 1-Apr-2021. Miller J, Martinez M and Margolis K (2021) Reply, Gastroenterology, 10.1053/j.gastro.2021.01.016, 160:5, (1888-1889), Online publication date: 1-Apr-2021. Henderson L, Canna S, Friedman K, Gorelik M, Lapidus S, Bassiri H, Behrens E, Ferris A, Kernan K, Schulert G, Seo P, Son M, Tremoulet A, Yeung R, Mudano A, Turner A, Karp D and Mehta J (2021) American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2, Arthritis & Rheumatology, 10.1002/art.41616, 73:4, Online publication date: 1-Apr-2021. Feldstein L, Tenforde M, Friedman K, Newhams M, Rose E, Dapul H, Soma V, Maddux A, Mourani P, Bowens C, Maamari M, Hall M, Riggs B, Giuliano J, Singh A, Li S, Kong M, Schuster J, McLaughlin G, Schwartz S, Walker T, Loftis L, Hobbs C, Halasa N, Doymaz S, Babbitt C, Hume J, Gertz S, Irby K, Clouser K, Cvijanovich N, Bradford T, Smith L, Heidemann S, Zackai S, Wellnitz K, Nofziger R, Horwitz S, Carroll R, Rowan C, Tarquinio K, Mack E, Fitzgerald J, Coates B, Jackson A, Young C, Son M, Patel M, Newburger J and Randolph A (2021) Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19, JAMA, 10.1001/jama.2021.2091, 325:11, (1074), Online publication date: 16-Mar-2021. Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrot M, Léger P, Galeotti C, Claude C, Wiedemann A, Lachaume N, Ovaert C, Dumortier M, Kahn J, Mandelcwajg A, Percheron L, Biot B, Bordet J, Girardin M, Yang D, Grimaud M, Oualha M, Allali S, Bajolle F, Beyler C, Meinzer U, Levy M, Paulet A, Levy C, Cohen R, Belot A, Angoulvant F, Rames C, Donzeau A, Lety S, Fedorczuk C, Lajus M, Bensaid P, Laoudi Y, Pons C, Beaucourt C, De Pontual L, Aupiais C, Lefevre-Utile A, Richard M, Goisque E, Iriart X, Brissaud O, Bailhache M, Segretin P, Molimard J, Orcel M, Benoist G, Amouyal E, Guerder M, Pouyau R, De Guillebon De Resnes J, Mezgueldi E, Cour-Andlauer F, Horvat C, Poinsot P, Frachette C, Ouziel A, Gillet Y, Barrey C, Brouard J, Faucon C, Ginies H, Ro V, Elanga N, Gajdos V, Basmaci R, Danekova N, Mutar H, Rouget S, Torterüe X, Nattes E, Hau I, Biscardi S, El Jurdi H, Jung C, Epaud R, Delestrain C, Carlier-Gonod A, Chavy C, Colomb B, Litzler-Renault S, Semama D, Huet F, Sarakbi M, Mortamet G, Bost-Bru C, Kevorkian-Verguet C, Lachaud M, Vinit C, Hentgen V, Leroux P, Bertrand V, Parrod C, Craiu I, Kone-Paut I, Durand P, Tissiere P, Morin L, Miatello J, Morelle G, Guiddir T, Borocco C, Guillot C, Leteurtre S, Dubos F, Jouancastay M, Recher M, Martinot A, Voeusler V, Languepin J, Morand A, Bosdure E, Bresson V, Vanel N, Ughetto F, Michel F, Marie C, Blonde R, Nguyen J, Garrec N, Chalvon-Demersay A, Masserot-Lureau C, Colas A, Ferrua C, Larakeb A, Benkaddouss S, Mathivon L, Monfort M, Naji S, Carbasse A, Milesi C, Schweitzer C, Giroux N, Boussard N, Romefort B, Launay E, Gras-Le Guen C, Ali A, Blot N, Tran A, Rancurel A, Haas H, Afanetti M, Bernardor J, Talmud D, Jhaouat I, Monceaux F, Chosidow A, Romain A, Grimprel E, Rambaud J, Jean S, Starck J, Levy Y, Guedj R, Carbajal R, Parisot P, Poncelet G, Wolff R, Lacarra B, Maroni A, Naudin J, Geslin G, Maurice L, Deho A, Lebourgeois F, Chomton M, Dauger S, Genuini M, Benzouid C, Lokmer J, Bonnefoy R, Melki I, Dingulu G, Gaschignard J, Ducrocq C, Pouletty M, Corseri O, Faye A, Rybak A, Titomanlio L, Hurtaux M, Garcelain G, Bonacorsi S, Bidet P, Birgy A, Renolleau S, Lesage F, Moulin F, Dupic L, de Saint Blanquat L, Heilbronner C, Vedrenne-Cloquet M, Salvador E, Bendavid M, De Marcellus C, Chareyre J, Pinhas Y, Brisse J, Taylor M, Debray, A, Adnot P, Chalumeau M, Abadie V, Frange P, Cohen J, Curtis W, Chappuy H, Belhadjer Z, Auriau J, Méot M, Houyel L, Bonnet D, Delacourt C, Drummond D, Bader-Meunier B, Quartier P, Delion F, Blanc P, Caron E, Maledon N, Robert B, Pantalone L, Kouider H, Loeile C, Loron G, Vittot C, Blanc T, Pinquier D, Buisson F, Flodrops H, Karim J, Sarton R, Mokraoui F, Escoda S, Deschamps N, Bonnemains L, Mahi S, Mertes C, Terzic J, Idier C, Benezech A, Simon T, Decramer S, Karsenty C, Brehin C, Chenichene S, Ursulescu N, Manteau C, Delattre M and Dalichoux B (2021) Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children, JAMA, 10.1001/jama.2021.0694, 325:9, (855), Online publication date: 2-Mar-2021. Bajolle F (2021) Syndrome inflammatoire avec atteinte multisystémique post-infection par le SARS-CoV-2 chez l'enfant : quand l'envisager et comment le prendre en charge ?, Perfectionnement en Pédiatrie, 10.1016/j.perped.2020.11.001, 4:1, (10-16), Online publication date: 1-Mar-2021. Lee J, Cho E and Lee H (2021) Multisystem Inflammatory Syndrome in Children (MIS-C), Pediatric Infection & Vaccine, 10.14776/piv.2021.28.e13, 28:2, (66), . December 8, 2020Vol 142, Issue 23 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.120.050147PMID: 33112651 Originally publishedOctober 28, 2020 Keywordssevere acute respiratory syndrome coronavirus 2pediatric multisystem inflammatory disease, COVID-19 relatedimmunoglobulins, intravenousheart failurePDF download Advertisement SubjectsHeart FailureInflammatory Heart Disease

Referência(s)